Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Scientific Officer | April 14, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date April 14, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2036-04-14 | Direct | 1,279,805 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Grant · Acquired 300,000 · Balance 1,279,805 F1: 75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter |
Filing footnotes · ownership attribution and instrument terms
F1: 75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed Apr 16, 2026 20:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 300,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001904824-26-000002 · ownership.xml · derivative · entry 1 Smeal Tod · CIK 0001904824 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,805 Underlying: Common Stock · 300,000 shares Expires 2036-04-14 F1 · derivative.exercise_date: 75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 20:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 332,621 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000950170-25-038698 · ownership.xml · derivative · entry 1 Smeal Tod · CIK 0001904824 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 979,805 Underlying: Common Stock · 332,621 shares Expires 2035-03-11 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:39 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 205,008 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001628280-24-009746 · wk-form4_1709854782.xml · derivative · entry 1 Smeal Tod · CIK 0001904824 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,184 Underlying: Common Stock · 205,008 shares Expires 2034-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:42 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 167,088 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001628280-23-008357 · wf-form4_167900293568224.xml · derivative · entry 1 Smeal Tod · CIK 0001904824 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,176 Underlying: Common Stock · 167,088 shares Expires 2033-03-15 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.